Previous 10 | Next 10 |
Sigyn Therapeutics (OTCQB: SIGY, SIGYD) , a development-stage medical technology company, announced the completion of a 1-for-40 reverse split of its common stock. According to the announcement, the reverse split was implemented on Jan. 31, 2024. “As a result of the split, the company ...
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, has announced a 1-for-40 reverse split of its common stock. The reverse split will go into effect tomorrow, Jan. 31, 2024. According to the company, its common stock will trade on a post-split basis at the beginnin...
2024-01-30 08:52:31 ET More on Sigyn Therapeutics, Inc. Financial information for Sigyn Therapeutics, Inc. Read the full article on Seeking Alpha For further details see: Sigyn Therapeutics to implement a 1-for-40 reverse stock split
SAN DIEGO, CA - ( NewMediaWire ) - January 30, 2024 - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced that a 1-for-40 reverse split of its common stock will be implemented tomorrow...
Sigyn Therapeutics (OTCQB: SIGY) is a development-stage medical technology company whose therapeutic candidates include Sigyn Therapy(TM), the ImmunePrep(TM) platform, ChemoPrep(TM), and ChemoPure(TM). “The company is advancing Sigyn Therapy to treat pathogen-associated inflammatory disor...
Sigyn Therapeutics in May 2023 announced patent and trademark applications for its ImmunePrep commercialization platform In October 2022, the company announced patent and trademark applications for ChemoPrep and ChemoPure to enhance chemotherapy and reduce toxicity Sigyn Therapeutics in Septe...
SAN DIEGO, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the release of a shareholder letter authored by Chairman and ...
2023-12-12 09:10:02 ET More on Sigyn Therapeutics, Inc. Financial information for Sigyn Therapeutics, Inc. For further details see: Sigyn Therapeutics names Jerry DeCiccio as finance cheif
SAN DIEGO, CA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the appointment of Jerry DeCiccio, CPA, MBA, as Chief Financi...
2023-11-15 09:55:46 ET More on Sigyn Therapeutics, Inc. Financial information for Sigyn Therapeutics, Inc. For further details see: Sigyn Therapeutics Inc GAAP EPS of -$0.02
News, Short Squeeze, Breakout and More Instantly...
Sigyn Therapeutics Inc Company Name:
SIGY Stock Symbol:
OTCMKTS Market:
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the company reported a loss from operations of $629,972, as compared to an operating loss of $521,258 for the compar...
SAN DIEGO, CA - ( NewMediaWire ) - May 15, 2024 - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the C...
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “Wh...